pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA
Olema Pharmaceuticals
Olema Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Chennai, IN
- Employees
- 2
- Programs
- 7
- Drugs
- 17
- Patents
- 8
Olema Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Olema Pharmaceuticals.
Olema Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
OP-1250-301
Olema Pharmaceuticals
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
1 trial -
OP-1250-302
Olema Pharmaceuticals
ER+, HER2- Advanced Breast Cancer
1 trial -
Palazestrant
Olema Pharmaceuticals
Breast Cancer
3 trials -
OP-1250
Olema Pharmaceuticals
Hormone Receptor Positive Breast Carcinoma
1 trial -
OP-3136
Olema Pharmaceuticals
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
1 trial -
Palazestrant
Olema Pharmaceuticals
Metastatic Breast Cancer
1 trial -
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Olema Pharmaceuticals
Advanced or Metastatic Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does Olema Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.